Show results for
Refine by
Lung Cell Suppliers Serving Ukraine
43 companies found
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T; Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo; Clear anti-cancer efficacy in an orthotopic model; Smaller number of 4th ...
based inDallas, TEXAS (USA)
Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past thirty years, Santa Cruz Biotechnology has focused on the ongoing development of research monoclonal antibodies, ...
Pheophorbide a is a chlorophyll-related compound studied for its anti-tumor and anti-cancer ...
based inCopenhagen V, DENMARK
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. We are led by an experienced ...
DuoBody PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed by Genmab under an agreement in which the companies share all ...
based inXiamen, CHINA
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® ...
Neurotrophic tropomyosin-related kinase (NTRK) is a group of high affinity nerve growth factor (NGF) receptors, including tropomyosin receptor kinases (Trk) A, B, and C which are encoded by NTRK1, NTRK2, and NTRK3 genes, respectively. NTRK proteins, ...
based inSarıyer, TURKEY
Virasoft Inc. was founded in 2015 with the support of the Turkish Ministry of Industry and Technology. We develop institution-specific projects in 4 main areas that meet all the needs of an institution in digital pathology. We focus on four main ...
Programmed cell death protein 1 (PD-1; also called CD279) is one of the co-inhibitory receptors that is expressed on the surface of antigen-stimulated T cells [1]. Normally, PD-L1 expression can be detected on ...
based inDaejeon, SOUTH KOREA
PANAGENE have been supplying Peptide Nucleic Acid (PNA) worldwide and exclusively since 2006 based on our unique invention of efficient synthesis of PNA with high purity, and nowadays we are possessing the best knowledge on PNA and the largest ...
PANAMutyper™ EML4-ALK Screening Kit is the qualitative diagnostic test kit which is able to detect 16 different EML4-ALK fusion genes of tissue from non-small cell lung cancer (NSCLC) patients using peptide ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
nfP2X7 is a tumour-specific form of the P2X7 ligand-gated ion channel, consisting of three identical protein subunits. When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of ...
based inSeoul, SOUTH KOREA
We make software that transforms medical data into deeper insight. Our AI technology takes medical intelligence to the next level: data-driven medicine. We aim to solve the most critical issues in cancer care today: reduce medical cost and prolong ...
Quantifying PD-L1 positivity with AI analysis; Finding more PD-L1 positive patients; Counting every PD-L1 positive tumor cell; Complex is what AI does ...
based inPrinceton, NEW JERSEY (USA)
Taiho Oncology, Inc. specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a ...
Tumors with specific FGFR aberrations: Solid tumors, Gastric cancer, Myelolymphoid neoplasms PHASE ...
based inShanghai, CHINA
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 5 ...
HANBEITAI (bevacizumab injection) was approved by the NMPA in November 2021. It is indicated for metastatic colorectal cancer (mCRC), advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian cancer and ...
based inAthens, GEORGIA (US) (USA)
Athens Research & Technology Inc. has been purifying human proteins and developing polyclonal antisera to those proteins since 1986. We specialize in highly pure, highly active human proteins. We routinely purify serine proteases, protease ...
based inHuzhou City, CHINA
Longterm medical is a world-leading custom wound dressings manufacturers that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. We design and supply medical solutions to enhance performance in healthcare – ...
Ultra-thin hydrocolloid dressing, is a 0.6mm wire thickness of flat wound dressing (minimum thickness to 0.3mm), an elastomeric dressing and composed of medical pressure sensitive adhesive, carboxy methyl cellulose (CMC) particles, etc. This ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients ...
based inVienna, AUSTRIA
ViennaLab Diagnostics specializes in easy-to-use in vitro diagnostic assays for the detection of genetic variants associated with genetic disorders, genetic predispositions, pharmacogenetics, cancer, and the human microbiome. Our focus is on product ...
A reliable tool to personalize therapy of lung cancer patients with acquired TKI-resistance mutation T790M in the EGFR ...
based inGlasgow, UNITED KINGDOM
We’re a leading microbiome therapeutics company. We have established proprietary MHRA licensed manufacturing capabilities and a supply chain model that enables us to leverage a pipeline of internal and partnered programmes around our lead asset, ...
Immuno-oncology exploits the mechanisms of the body’s own natural immune response, either by stimulating or suppressing it, to fight ...
based inNew York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
XPO1 has been shown to regulate nuclear export of many of the major tumor suppressor proteins and oncogenic cell growth regulators. Overexpression of XPO1 has been reported in many cancer types and is associated with aggressive tumor behavior and ...
based inVancouver, BRITISH COLUMBIA (CANADA)
STEMCELL Technologies provides high-quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources to scientists around the world working on stem cell, immunology, cancer, regenerative medicine, ...
Interleukin 2 (IL-2) is a monomeric cytokine that was originally identified as a T cell growth factor (Gaffen & Liu). It binds to heterotrimeric receptors consisting of CD25, CD122, and CD132. Upon binding, it activates JAK3-, STAT5-, and ...
based inOlivos, ARGENTINA
With a strong development platform and four production sites, AMEGA Biotech develops and produces biosimilars. Exporting recombinant proteins worldwide and focused on central markets registrations, AMEGA Biotech is the leading regional producer.. ...
Interferons are a group of antiviral proteins produced in reaction to viral infections. It boosts the resistance of surrounding cells to attacks by viruses, inhibits viral multiplication and modifies the body’s response. Interferon beta is ...